Search Results

Nordic Nanovector - Completion of annual general meeting

Reference is made to the stock exchange announcement made by Nordic Nanovector ASA on 6 June 2023 regarding the Company’s acquisition of Thor Medical AS, with approval of the Transaction from the Company’s annual general meeting as one of the closing conditions.

June 28, 2023

·

1 min read

Press Releases

Bavarian Nordic’s Chikungunya Vaccine Receives Recommendation from U.S. CDC’s Advisory Committee on Immunization Practices (ACIP)

April 17, 2025

·

6 min read

Business

Nordic Nanovector - Appointment of Alf Bjørseth as CEO

Reference is made to the stock exchange announcement made earlier by Nordic Nanovector ASA, where the Company announced, among other things, that the annual general meeting had elected new board members to the board of directors, including electing former interim CFO & CEO Ludvik Sandnes as new chairman.

June 28, 2023

·

1 min read

Nordic Nanovector - Annual and Remuneration Reports Approved

On 22 March 2023, the Board of Directors of Nordic Nanovector ASA approved the Company’s financial statements for 2022.

March 23, 2023

·

1 min read

Nordic Nanovector - Annual General Meeting Postponed

The Board of Directors of Nordic Nanovector ASA has decided to postpone the upcoming Annual General Meeting, which was originally scheduled for 26 April.

March 31, 2023

·

1 min read

Nordic Nanovector - Notice of Annual General Meeting on 28 June 2023

Notice is given that the Annual General Meeting of Nordic Nanovector ASA will be held on 28 June 2023, at 14:00 hours CEST at Advokatfirmaet CLP, Sommerrogata 13-15, 0255 Oslo.

June 7, 2023

·

1 min read

Press Releases

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension)

April 25, 2025

·

3 min read

Press Releases

Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S

April 10, 2025

·

2 min read

Business

Nordic Nanovector ASA Results for the Second Half and Full Year 2022

Nordic Nanovector ASA announces its results for the second half and full year 2022. A presentation by Nordic Nanovector’s interim CEO & CFO, Ludvik Sandnes will be held in-person in Oslo and webcast live beginning at 8:30am CET - details below.

February 28, 2023

·

8 min read

Press Releases

Bavarian Nordic Receives Marketing Authorization for Chikungunya Vaccine for Persons Aged 12 and Older in the United Kingdom

May 2, 2025

·

5 min read